The pharmaceutical industry in Australia is facing a crisis, with patients missing out on life-changing treatments due to a complex and lengthy approvals process. This is despite the fact that only a quarter of new medicines launched globally in the last decade have been subsidised in Australia. The situation is particularly dire for those with rare diseases, such as Tina Powney, who has been living with IPAH for 26 years and has had to endure a constant battle for access to essential medications. The issue is further exacerbated by the Trump administration's global pricing pressures, which are pushing drug companies to avoid launching their products in smaller and lower-priced markets, such as Australia. This has led to a situation where patients are missing out on treatments that are already helping people elsewhere, and the industry is warning that the situation is becoming untenable. The Australian government is aware of the issue and has commissioned a Health Technology Assessment (HTA) review to speed up approvals and improve reimbursement pathways. However, the industry argues that the task has been made more urgent as the Trump administration tries to bring medicine prices down in the US, which could further marginalise Australia's already struggling pharmaceutical sector. The situation is a stark reminder of the importance of investing in innovative medicines and the need for a more efficient and responsive approvals process. It also highlights the need for a more balanced approach to pricing, one that takes into account the cost of innovation and the value of new treatments to patients. The future of healthcare in Australia depends on these reforms, and it is crucial that the government acts swiftly to address this crisis.
